ClinicalTrials.gg
CompletedNCT00295789Updated Sep 22, 2016

Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)

A Phase 3 interventional study of chemotherapy: Paclitaxel/Cisplatin and chemotherapy: Paclitaxel/Carboplatin in Uterine Cervical Neoplasms, sponsored by Haruhiko Fukuda. Completed at 30 sites in Japan. Open to female participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-09-22.

Sponsored by Haruhiko Fukuda · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
253
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Uterine Cervical Neoplasms with a site in Japan — 15 open to participants now, 23 under way, 3 of them phase 3. Uterine Cervical Neoplasms · Japan.

Enrollment
29th of 45
253 · median 384
Started
2006
the only one that year
Phase 3
15 of 49
2 open now
Registered
3rd of 49
by date
Lead sponsor
2 of 49
Haruhiko Fukuda

Among the 49 studies in Uterine Cervical Neoplasms with a site in Japan, this one is the 29th largest by enrollment of the 45 interventional ones that give a count, is the only one that started in 2006, is one of 15 in phase 3, and was the 3rd registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

15 of the 49 studies in Uterine Cervical Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 20 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Uterine Cervical Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

To evaluate the clinical benefits of Paclitaxel plus Carboplatin compared with Paclitaxel plus Cisplatin in Stage IVb, Persistent, or Recurrent Cervical Cancer

Read the detailed description

Prognosis of the advanced, recurrent, or persistent cervical cancer, which is not amenable to curative treatment with surgery and/or radiation therapy, still remains poor. Recently, cisplatin plus paclitaxel for palliative chemotherapy were reported to improve the response rate and progression-free interval compared to cisplatin alone and has been shown as a new appropriate regimen. However, more effective and/or less toxic combinations are needed. Carboplatin as a single agent has less response rate but less overall toxicity than cisplatin. Particularly, because less nephrotoxicity does not require hydration and less neurotoxicity enables 3hrs administration of paclitaxel in the combination, out patient therapy becomes possible and patients' quality of life must improve. Therefore, we planned to evaluate the benefits of less toxicity of the chemotherapy containing paclitaxel and carboplatin, which could reduce the hospitalised days, in comparison with the standard chemotherapy containing paclitaxel and cisplatin. This clinical trial is targeted on the patients in Japan with incurable cervical cancer diagnosed by means of image.

03

Conditions studied

  • Uterine Cervical Neoplasms

Keywords

  • cervical cancer
  • palliative chemotherapy
  • recurrent
  • persistent
  • stageⅣb
  • cisplatin
  • carboplatin
  • paclitaxel
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. proven uterine cervical cancer
  2. squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the uterine cervix
  3. one of the followings, 1)primary stage Ⅳb cervical cancer, 2)the first relapse or persistent cervical cancer after curative treatments, 3)the second relapse or persistent cervical cancer after curative second line treatments including radiation, systemic chemotherapy, hormonal therapy, or vaccination therapy for the first relapse
  4. Patients may have been previously treated with less than 50 Gy of palliative radiation therapy
  5. Patients have received no prior treatment or a certain interval must have elapsed from the last administration of previous treatments including palliative radiation therapy
  6. one of the followings, 1)There is at least one lesion outside the pelvic cavity except paraaortic LN and/or inguinal LN, 2)There is no metastatic lesion outside the pelvic cavity except paraaortic LN and/or inguinal LN and some of the lesions have been irradiated, 3)All lesions are localized inside the pelvic cavity, and some of them have been irradiated
  7. no prior surgical therapy for metastatic lesions of the lung or inside the pelvic cavity
  8. no bilateral hydronephrosis
  9. no prior chemotherapy including more than two platinum-containing regimens
  10. no prior chemotherapy including taxane
  11. age: 20 to75 years
  12. PS: 0-2
  13. ANC ≧1,500 /mm3, Plt≧10.0×104/mm3, T-bil≦1.5 mg/dl, GOT()≦100IU/l, sCre ≦1.2 mg/dl, Ccr≧50ml/min in using the equation, and normal
  14. written

Exclusion criteria

Exclusion Criteria:

  1. patients who have some neurologically functional disorder
  2. symptomatic
  3. hypersensitive to alcohol
  4. active infection
  5. HBs antigen positive
  6. uncontrollable hypertension
  7. history of myocardiac infarction within six months
  8. unstable angina
  9. uncontrollable diabetes
  10. Patients with a concomitant or prior invasive (except intramucosal malignancy which are curable with local therapy) who have had any evidence of the disease within the last 5 years
  11. women during pregnancy or breast-feeding
  12. patients with psychiatric illness
  13. patients who have been treated with the systemic medication
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
253 participants (actual)

Study arms

  • Active comparator
    1

    Drug: chemotherapy: Paclitaxel/Cisplatin

    Drug: chemotherapy: Paclitaxel/Cisplatin

  • Experimental
    2

    Drug: chemotherapy: Paclitaxel/Carboplatin

    Drug: chemotherapy: Paclitaxel/Carboplatin

Interventions

  • Drugchemotherapy: Paclitaxel/Cisplatin

    Drug page: TP protocolStudies of TP protocolTP protocol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Drug: chemotherapy: Paclitaxel/Cisplatin

  • Drugchemotherapy: Paclitaxel/Carboplatin

    Drug: chemotherapy: Paclitaxel/Carboplatin

06

What researchers measure

Primary outcomes

  1. overall survival

    Time frame: During the study conduct

Secondary outcomes

  1. progression-free survival

    Time frame: During the study conduct

  2. response rate

    Time frame: During the study conduct

  3. adverse events

    Time frame: During the study conduct

  4. severe adverse events

    Time frame: During the study conduct

  5. proportion of periods of non-hospitalization to those of the planned treatment

    Time frame: 18 weeks

07

Study locations

30 sites
  • Aichi Cancer Center Hospital
    Nagoya,Chikusa-ku,Kanokoden,1-1, Aichi 464-8681, Japan
  • Nagoya Medical Center
    Nagoya,Naka-ku,Sannomaru,4-1-1, Aichi 460-0001, Japan
  • National Hospital Organization Shikoku Cancer Center
    Matsuyama,Horinouchi,13, Ehime 790-0007, Japan
  • Kyushu University Hospital
    Fukuoka,Higashi-ku,Maidashi,3-1-1, Fukuoka 812-8582, Japan
  • National Kyushu Cancer Center
    Fukuoka,Minami-ku,Notame,3-1-1, Fukuoka 811-1395, Japan
  • Kurume University School of Medicine
    Kurume, Asahi-machi, 67, Fukuoka 830-0011, Japan
  • Gunma Prefectural Cancer Center
    Ota,Takabayashi-nishi-cho,617-1, Gunma 373-8550, Japan
  • National Hospital Organization Kure Medical Center Chugoku Cancer Center
    Kure,Aoyama-cho,3-1, Hiroshima 737-0023, Japan
  • Hokkaido University Hospital
    North-14 West-5 Kita-ku,Sapporo, Hokkaido 060-8648, Japan
  • Sapporo Medical University
    S-1,W-16,Chuo-ku,Sapporo, Hokkaido 060-8543, Japan
  • Hyogo Medical Center for Adults
    Akashi,Kitaouji-cho,13-70, Hyogo 673-8558, Japan
  • Institute of Clinical Medicine,Tsukuba University Hospital
    Tsukuba,Tennodai,1-1-1, Ibaraki 305-8575, Japan
  • Kagoshima City Hospital
    Kagoshima,Kajiya-cho,20-17, Kagoshima 892-8580, Japan
  • Tohoku University Hospital
    Sendai,Aoba-ku,Seiryo-machi,1-1, Miyagi 980-8574, Japan
  • Sinshu University
    Matsumoto,Asahi,3-1-1, Nagano 390-8621, Japan
  • Nagaoka Red Cross Hospital
    Nagaoka,Terashima-cho,297-1, Niigata 940-2085, Japan
  • Niigata Cancer Center Hospital
    Niigata,Kawagishi-cho,2-15-3, Niigata 951-8566, Japan
  • Osaka Medical Center for Cancer and Cardiovascular Diseases
    Osaka,Higashinari-ku,Nakamichi,1-3-3, Osaka 537-8511, Japan
  • Osaka City General Hospital
    Osaka,Miyakojima-ku,Miyakojimahondori,2-13-22, Osaka 534-0021, Japan
  • Kinki University School of Medicine
    Osaka-Sayama,Ohno-higashi,377-2, Osaka 589-8511, Japan
  • Faculty of Medicine, Saga University
    Saga,Nabeshima,5-1-1, Saga 849-8501, Japan
  • Saitama Medical Center, Saitama Medical School
    Kawagoe,Komoda,1981, Saitama 350-8550, Japan
  • Saitama Cancer Center
    Kita-adachi,Ina,Komuro,818, Saitama 362-0806, Japan
  • National Defense Medical College
    Tokorozawa,Namiki,3-2, Saitama 359-8513, Japan
  • Juntendo University School of Medicine
    Bunkyo-ku,Hongo,3-1-3, Tokyo 113-0033, Japan
  • The University of Tokyo Hospital
    Bunkyo-ku,Hongo,7-3-1, Tokyo 113-8655, Japan
  • National Cancer Center Hospital
    Chuo-ku,Tsukiji,5-1-1, Tokyo 104-0045, Japan
  • Cancer Institute Hospital
    Koto-ku,Ariake,3-10-6, Tokyo 135-8550, Japan
  • Jikei University Hospital
    Minato-ku,Nishishinbashi,3-25-8, Tokyo 105-8461, Japan
  • Tottori University School of Medicine
    Yonago,Nishimachi,36-1, Tottori 683-8504, Japan
08

References and documents

Publications

  • Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, Nishimura S, Ushijima K, Takano M, Satoh T, Yoshikawa H. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. J Clin Oncol. 2015 Jul 1;33(19):2129-35. doi: 10.1200/JCO.2014.58.4391. Epub 2015 Mar 2. PubMed 25732161 ↗

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2006
First posted
Feb 24, 2006
Start
Feb 2006
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Last update
Sep 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00295789
Lead sponsor
Haruhiko Fukuda
Collaborators
Ministry of Health, Labour and Welfare, Japan
Responsible party
Haruhiko Fukuda (JCOG Data Center, Japan Clinical Oncology Group) — Sponsor-investigator
First posted
Feb 24, 2006
Start date
Feb 2006
Primary completion
Nov 2011
Completion
Nov 2011
Last update
Sep 22, 2016

Study contacts

Toshiharu Kamura, MD, PhD
study chair · Kurume University School of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion